Clinical Trial Update: A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer [Phase 2]

View source ↗

Summary

Phase II clinical study to evaluate HLX43 in combination with Serplulimab for advanced lung cancer; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• HLX43
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING